2025
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis
Shah T, Zhang Z, Shah H, Fanaroff A, Nathan A, Parise H, Lutz J, Sugeng L, Bellumkonda L, Redfors B, Omerovic E, Petrie M, Vora A, Fiorilli P, Kobayashi T, Ahmad Y, Forrest J, Giri J, Herrmann H, Lansky A. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. JACC Cardiovascular Interventions 2025, 18: 738-748. PMID: 39985508, DOI: 10.1016/j.jcin.2024.11.036.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsCotransporter-2 inhibitorsAortic stenosisEffects of sodium-glucose cotransporter-2 inhibitorsProgression of aortic stenosisBaseline AS severityAssociated with slower progressionEchocardiographic follow-upRetrospective electronic medical record dataAortic valve sclerosisDisease-related morbidityChronic kidney diseaseSGLT2i usageRates of diabetesSevere ASAS severityEjection fractionFollow-upPrimary outcomeGt;1 yearKidney diseaseMedical record dataYale New Haven Health SystemPatientsObservational study
2024
A Multimodal Video-Based AI Biomarker for Aortic Stenosis Development and Progression
Oikonomou E, Holste G, Yuan N, Coppi A, McNamara R, Haynes N, Vora A, Velazquez E, Li F, Menon V, Kapadia S, Gill T, Nadkarni G, Krumholz H, Wang Z, Ouyang D, Khera R. A Multimodal Video-Based AI Biomarker for Aortic Stenosis Development and Progression. JAMA Cardiology 2024, 9: 534-544. PMID: 38581644, PMCID: PMC10999005, DOI: 10.1001/jamacardio.2024.0595.Peer-Reviewed Original ResearchCardiac magnetic resonanceAortic valve replacementCardiac magnetic resonance imagingAV VmaxSevere ASAortic stenosisCohort studyPeak aortic valve velocityCohort study of patientsAortic valve velocityCohort of patientsTraditional cardiovascular risk factorsAssociated with faster progressionStudy of patientsCedars-Sinai Medical CenterAssociated with AS developmentCardiovascular risk factorsCardiovascular imaging modalitiesIndependent of ageModerate ASEjection fractionEchocardiographic studiesValve replacementRisk stratificationCardiac structurePredictors of Disease Progression and Adverse Clinical Outcomes in Patients With Moderate Aortic Stenosis Using an Artificial Intelligence-Based Software Platform
Salem M, Gada H, Ramlawi B, Sotelo M, Nona P, Wagner L, Rogers C, Brigman L, Vora A. Predictors of Disease Progression and Adverse Clinical Outcomes in Patients With Moderate Aortic Stenosis Using an Artificial Intelligence-Based Software Platform. The American Journal Of Cardiology 2024, 223: 92-99. PMID: 38710350, DOI: 10.1016/j.amjcard.2024.04.051.Peer-Reviewed Original ResearchConceptsAdverse clinical outcomesRisk of adverse clinical outcomesModerate aortic stenosisClinical outcomesAortic stenosisDisease progressionSevere ASModerate ASAtrial fibrillationAmerican Heart Association/American College of Cardiology guidelinesLower left ventricular ejection fractionAssociated with adverse clinical outcomesPredictor of clinical outcomePredictors of disease progressionAmerican Heart Association/American CollegeFactors associated with outcomesVentricular ejection fractionEnd-stage renal diseaseHeart failure hospitalizationCox proportional hazards modelsProportional hazards modelSerial echoesAS severityEjection fractionCardiology guidelines
2023
The Current Landscape of Transcatheter Tricuspid Valve Intervention
Seligman H, Vora A, Haroian N, Puri R, Heng E, Smith R, Latib A, Makkar R, Sorajja P, Leon M, Ahmad Y. The Current Landscape of Transcatheter Tricuspid Valve Intervention. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101201. PMID: 39131057, PMCID: PMC11307702, DOI: 10.1016/j.jscai.2023.101201.Peer-Reviewed Original ResearchTricuspid regurgitationHeart failureTranscatheter tricuspid valve interventionCaval valve implantationRight heart failureWorse tricuspid regurgitationPulmonary artery pressureReduced ejection fractionSevere tricuspid regurgitationAge-adjusted prevalenceMainstay of therapyTricuspid valve interventionMore contemporary dataArtery pressureValve implantationEjection fractionValve interventionAdverse prognosisValve repairTranscatheter interventionsTR severityPrevalence increasesPotential rolePatientsContemporary data
2018
Transcatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction
Lowenstern A, Vora A, Dunning A, Schulte P, Vemulapalli S, Hughes G, Velazquez E, Harrison J, Samad Z. Transcatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction. Structural Heart 2018, 2: 388-395. DOI: 10.1080/24748706.2018.1500049.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementCoronary artery bypass graftSevere aortic stenosisVentricular systolic dysfunctionAortic valve replacementAortic stenosisMedical managementSystolic dysfunctionValve replacementOutcomes of patientsArtery bypass graftVentricular ejection fractionIschemic heart diseaseCause mortalityMultivariable adjustmentRenal insufficiencyTAVR patientsTransthoracic echocardiogramEjection fractionHeart failureMedian ageBypass graftHistorical cohortTherapeutic optionsPatient population
2016
Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction
Wang T, Vora A, Peng S, Fonarow G, Das S, de Lemos J, Peterson E. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. Journal Of The American Heart Association 2016, 5: e002612. PMID: 26796254, PMCID: PMC4859378, DOI: 10.1161/jaha.115.002612.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAge FactorsAgedAged, 80 and overDatabases, FactualDrug PrescriptionsDrug Utilization ReviewFemaleHeart FailureHumansHyperkalemiaMaleMedicareMineralocorticoid Receptor AntagonistsMyocardial InfarctionPractice Patterns, Physicians'RegistriesRisk AssessmentRisk FactorsSpironolactoneStroke VolumeTime FactorsTreatment OutcomeUnited StatesConceptsRisk of hyperkalemiaAcute renal failureAldosterone antagonistsAldosterone antagonist useAssociated with lower mortalityEjection fractionOlder MI patientsAntagonist useRenal failureRisk of acute renal failureAngiotensin-converting enzyme inhibitor/angiotensin receptor blockerMI patientsSymptomatic HF patientsLow ejection fractionAssociated with increased riskReduced ejection fractionInhibitor/angiotensin receptor blockerAldosterone antagonist therapyLower mortalityACTION Registry-GWTGPost-myocardial infarctionAcute myocardial infarctionAntagonist therapyReceptor blockersOlderly patients
2014
Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease Insights From the REMIT Study
Samad Z, Boyle S, Ersboll M, Vora AN, Zhang Y, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers JG, O’Connor C, Velazquez EJ, Jiang W, Investigators R. Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease Insights From the REMIT Study. Journal Of The American College Of Cardiology 2014, 64: 1669-1678. PMID: 25323254, PMCID: PMC4752118, DOI: 10.1016/j.jacc.2014.04.087.Peer-Reviewed Original ResearchConceptsMental stress-induced myocardial ischemiaIschemic heart diseaseStable ischemic heart diseaseLeft ventricular ejection fractionPlatelet aggregation responseMental stress taskMental stressTransthoracic echocardiographyPlatelet reactivityStress-induced myocardial ischemiaIschemic ST-segment changesRegional wall motion abnormalitiesAggregation responseStress taskMost baseline characteristicsVentricular ejection fractionHigher baseline depressionLong-term outcomesST-segment changesWall motion abnormalitiesPlatelet aggregation studiesSex differencesBaseline characteristicsBlood pressureEjection fraction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply